N/A
N=120
Prospective Feasibility Trial of AccuCath 2.25" Blood Control (BC) Placed in Difficult Access Patients in the Emergency Department
Vascular Access Complication
Bottom Line
View on ClinicalTrials.gov: NCT02449798 ↗Enrolled (actual)
120
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: First Attempt Success Rate — 92 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- AccuCath 2.25" BC Intravascular Catheter (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- C. R. Bard
- Primary completion
- Jun 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY First Attempt Success Rate |
92 | — |
| PRIMARY Number of Catheter Attempts Required to Complete Successful PIV Placement |
1 | — |
| SECONDARY Time to Catheter Placement |
2 | — |
| SECONDARY Complications |
18 | — |
| SECONDARY Dwell Time |
90.98 | — |
| SECONDARY Completion of Therapy |
102 | — |
| SECONDARY Patient Satisfaction |
5 | — |
| SECONDARY Patient Satisfaction |
5 | — |
Summary
Study objective is to evaluate user preference, time for procedure, insertion success rates, complications, completion of therapy and dwell time of the AccuCath 2.25" BC device placed in difficult IV access patients in the emergency department.
Eligibility Criteria
Inclusion Criteria
- Male or female, age > 18 years old;
- Capable and willing to give informed consent;
- English speaking;
- Acceptable candidate for an elective, non-emergent peripheral IV as determined by ordering physician;
- Admitted to inpatient area for minimum of 24 hours, preferably for average hospital length of stay;
- Difficult venous access patient as defined by either 2 failed initial attempts without ultrasound guidance or a history of difficult access plus the inability to directly visualize or palpate a target vein.
Exclusion Criteria
- Male or female, < 18 years old;
- Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);
- Previous venous grafts or surgery at the target vessel access site;
- Subjects with lymphedema or status-post mastectomy on affected side;
- Currently involved in other investigational clinical trials (unless permission is granted by other study PI).
Data sourced from ClinicalTrials.gov (NCT02449798). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.